biologic therapy mesa: help for a joint that stays sore

Lighter work and easy motion may settle soreness

Take a break from the motion that brought on soreness. Still, don't spend the whole day sitting. Gentle motion may limit added stiffness. Walk less far or choose an easier chore. Then notice whether the joint feels worse later. A cold pack may ease pain that has just grown stronger. Heat may feel better when stiffness bothers you more than swelling. Wrap either pack in a towel before it touches your skin.

Don't push through a sharp jab. If the same exercise makes things worse each time, stop and call your doctor. Ask whether a pain medicine is safe with all your other pills.

Lost sleep or hard daily tasks make an exam worthwhile

Book an exam when soreness breaks your sleep or makes walking, bathing, dressing, or reaching hard. Don't wait when the joint is hot, red, badly swollen, or almost impossible to move. A fever with joint heat needs prompt care. After a fresh injury, get quick help if the joint is bent out of place or won't hold your weight.

At a regular visit, you'll talk about the ache's first day and painful motions. The examiner will move the joint and press on sore areas. Bring a record of your pills and any earlier X-ray notes. Ask, “Which part is sore, and which motions are safe?”

At QC Kinetix, regenerative treatments are shots prepared using blood, and a medical provider checks the joint first; ask whether the person doing yours is a doctor before you agree.

Sources

1. RESTORE, the largest and most rigorously blinded placebo-controlled PRP trial in knee OA (n=288, participant-, injector- and assessor-blinded), gave three weekly injections of a commercial leukocyte-poor PRP or saline. At 12 months the change in knee pain was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and the change in medial tibial cartilage volume was -1.4% vs -1.2% (difference -0.2%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no between-group difference. The authors concluded the findings do not support the use of PRP for knee OA.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

2. The largest head-to-head trial of cell-based orthobiologics to date randomised 480 patients with KL II-IV knee OA across four arms: autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, allogeneic umbilical cord tissue-derived MSCs, and a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another or to the corticosteroid control on either co-primary endpoint (VAS pain, KOOS pain), and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events were reported.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature Medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

3. A meta-analysis of the PLACEBO arms of 73 double-blind trials (5,895 patients) quantified what a saline knee injection alone achieves: statistically and clinically significant improvement in pain, function and quality of life at 1, 3 and 6 months, with responder rates exceeding 50% at all three time points, peaking around 4-8 months and declining by 12 months. Placebo response was stronger in trials with more female participants and in more recently published trials.

   Previtali D, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression.. EFORT Open Reviews, 2025. DOI: 10.1530/EOR-2025-0022.

4. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.